GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » EPS without NRI

Biodesix (Biodesix) EPS without NRI : $-0.63 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Biodesix EPS without NRI?

Biodesix's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.10. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.63.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 53.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Biodesix's EPS without NRI or its related term are showing as below:

BDSX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.2   Med: -23.6   Max: 53.1
Current: 53.1

During the past 6 years, Biodesix's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 53.10% per year. The lowest was -37.20% per year. And the median was -23.60% per year.

BDSX's 3-Year EPS without NRI Growth Rate is ranked better than
89.71% of 175 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.2 vs BDSX: 53.10

Biodesix's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.65.

Biodesix's EPS (Basic) for the three months ended in Dec. 2023 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.65.


Biodesix EPS without NRI Historical Data

The historical data trend for Biodesix's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix EPS without NRI Chart

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.54 -6.05 -1.61 -1.38 -0.62

Biodesix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.24 -0.17 -0.12 -0.10

Competitive Comparison of Biodesix's EPS without NRI

For the Diagnostics & Research subindustry, Biodesix's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodesix's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Biodesix's PE Ratio without NRI falls into.



Biodesix EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biodesix  (NAS:BDSX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biodesix EPS without NRI Related Terms

Thank you for viewing the detailed overview of Biodesix's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodesix (Biodesix) Business Description

Traded in Other Exchanges
N/A
Address
2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Executives
Scott Hutton director, officer: President & CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane officer: Chief Commercial Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano officer: Chief Development Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie officer: CFO, Sec'y & Treasurer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez officer: Chief Accounting Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem director 5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr director, 10 percent owner C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek officer: Chief Accounting Officer 6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience director, 10 percent owner, other: Chairman 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii director, officer: SVP, Rsrch & Trans'l Science 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139